Standard
The therapeutic potential of psychedelics : the European regulatory perspective. / Butlen-Ducuing, Florence; McCulloch, Drummond E.Wen; Haberkamp, Marion; Mattila, Taina; Bałkowiec-Iskra, Ewa; Aislaitner, Georgios; Balabanov, Pavel; Lundberg, Johan; Stenbæk, Dea Siggaard; Elferink, Andre; Knudsen, Gitte M.; Thirstrup, Steffen.
I:
The Lancet, Bind 401, Nr. 10378, 2023, s. 714-716.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
Butlen-Ducuing, F, McCulloch, DEW, Haberkamp, M, Mattila, T, Bałkowiec-Iskra, E, Aislaitner, G, Balabanov, P, Lundberg, J
, Stenbæk, DS, Elferink, A
, Knudsen, GM & Thirstrup, S 2023, '
The therapeutic potential of psychedelics: the European regulatory perspective',
The Lancet, bind 401, nr. 10378, s. 714-716.
https://doi.org/10.1016/S0140-6736(23)00264-7APA
Butlen-Ducuing, F., McCulloch, D. E. W., Haberkamp, M., Mattila, T., Bałkowiec-Iskra, E., Aislaitner, G., Balabanov, P., Lundberg, J.
, Stenbæk, D. S., Elferink, A.
, Knudsen, G. M., & Thirstrup, S. (2023).
The therapeutic potential of psychedelics: the European regulatory perspective.
The Lancet,
401(10378), 714-716.
https://doi.org/10.1016/S0140-6736(23)00264-7Vancouver
Butlen-Ducuing F, McCulloch DEW, Haberkamp M, Mattila T, Bałkowiec-Iskra E, Aislaitner G o.a.
The therapeutic potential of psychedelics: the European regulatory perspective.
The Lancet. 2023;401(10378):714-716.
https://doi.org/10.1016/S0140-6736(23)00264-7Author
Butlen-Ducuing, Florence ; McCulloch, Drummond E.Wen ; Haberkamp, Marion ; Mattila, Taina ; Bałkowiec-Iskra, Ewa ; Aislaitner, Georgios ; Balabanov, Pavel ; Lundberg, Johan ; Stenbæk, Dea Siggaard ; Elferink, Andre ; Knudsen, Gitte M. ; Thirstrup, Steffen. / The therapeutic potential of psychedelics : the European regulatory perspective. I: The Lancet. 2023 ; Bind 401, Nr. 10378. s. 714-716.
Bibtex
@article{9fc0dadacfa841c8869a9b16ea23e876,
title = "The therapeutic potential of psychedelics: the European regulatory perspective",
author = "Florence Butlen-Ducuing and McCulloch, {Drummond E.Wen} and Marion Haberkamp and Taina Mattila and Ewa Ba{\l}kowiec-Iskra and Georgios Aislaitner and Pavel Balabanov and Johan Lundberg and Stenb{\ae}k, {Dea Siggaard} and Andre Elferink and Knudsen, {Gitte M.} and Steffen Thirstrup",
note = "Funding Information: ST reports consulting fees paid directly to his former employee from Cybin, a pharmaceutical company developing psychedelics (no personal payment). DE-WM reports a PhD stipend paid for by an unrestricted grant from COMPASS Pathways, a commercial company involved in trials of psychedelic substances for mental health conditions, that had no involvement in the writing of this Comment. GMK reports grants or contracts from Lundbeck Foundation, Novo Nordisk Foundation, Danish Research Council, the EU and other funding bodies; payment or honoraria from Sage Biogen, Onsero, Pangea, H Lundbeck, and Angelini for consulting, lectures, presentations, or educational events; participation on data safety monitoring board or advisory board for the Human Brain Project, IMIM, Barcelona, and SGK Foundation; is a past President of the ECNP (not paid); and has Novo Nordisk stock options unrelated to the topic discussed (Novo Nordisk has no current therapies under investigation in this field). JL reports grants from the Swedish Research Council, lecture honorarium from Novartis, and financial support and in-kind work to provide investigational products (niacin and psilocybin) for researcher initiated phase 2b trial PSIPET (EudraCT-number: 2020-002790-94) from the non-profit Osmond Foundation. DSS reports grants from the Independent Research Fund Denmark, the Heath Foundation, and the Nordic Research Council; honoraria as speaker for the Lundbeck Foundation; and is a paid scientific adviser for Clerkenwell Health, a commercial company involved in trials of psychedelic substances for mental health conditions. The other authors declare no competing interests. This Comment comes from a collaboration between the EMA, the EMA's Central Nervous System Working Party, and the ECNP. The views expressed in this Comment are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organisations with which the authors are employed or affiliated.",
year = "2023",
doi = "10.1016/S0140-6736(23)00264-7",
language = "English",
volume = "401",
pages = "714--716",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10378",
}
RIS
TY - JOUR
T1 - The therapeutic potential of psychedelics
T2 - the European regulatory perspective
AU - Butlen-Ducuing, Florence
AU - McCulloch, Drummond E.Wen
AU - Haberkamp, Marion
AU - Mattila, Taina
AU - Bałkowiec-Iskra, Ewa
AU - Aislaitner, Georgios
AU - Balabanov, Pavel
AU - Lundberg, Johan
AU - Stenbæk, Dea Siggaard
AU - Elferink, Andre
AU - Knudsen, Gitte M.
AU - Thirstrup, Steffen
N1 - Funding Information:
ST reports consulting fees paid directly to his former employee from Cybin, a pharmaceutical company developing psychedelics (no personal payment). DE-WM reports a PhD stipend paid for by an unrestricted grant from COMPASS Pathways, a commercial company involved in trials of psychedelic substances for mental health conditions, that had no involvement in the writing of this Comment. GMK reports grants or contracts from Lundbeck Foundation, Novo Nordisk Foundation, Danish Research Council, the EU and other funding bodies; payment or honoraria from Sage Biogen, Onsero, Pangea, H Lundbeck, and Angelini for consulting, lectures, presentations, or educational events; participation on data safety monitoring board or advisory board for the Human Brain Project, IMIM, Barcelona, and SGK Foundation; is a past President of the ECNP (not paid); and has Novo Nordisk stock options unrelated to the topic discussed (Novo Nordisk has no current therapies under investigation in this field). JL reports grants from the Swedish Research Council, lecture honorarium from Novartis, and financial support and in-kind work to provide investigational products (niacin and psilocybin) for researcher initiated phase 2b trial PSIPET (EudraCT-number: 2020-002790-94) from the non-profit Osmond Foundation. DSS reports grants from the Independent Research Fund Denmark, the Heath Foundation, and the Nordic Research Council; honoraria as speaker for the Lundbeck Foundation; and is a paid scientific adviser for Clerkenwell Health, a commercial company involved in trials of psychedelic substances for mental health conditions. The other authors declare no competing interests. This Comment comes from a collaboration between the EMA, the EMA's Central Nervous System Working Party, and the ECNP. The views expressed in this Comment are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organisations with which the authors are employed or affiliated.
PY - 2023
Y1 - 2023
U2 - 10.1016/S0140-6736(23)00264-7
DO - 10.1016/S0140-6736(23)00264-7
M3 - Comment/debate
C2 - 36780909
AN - SCOPUS:85149396037
VL - 401
SP - 714
EP - 716
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10378
ER -
